**Appendix 1- US and UK cardiovascular prevention guideline targets**

*Methods*

Achievement of targets for US and UK guidelines for blood pressure (BP), cholesterol and antiplatelet therapy for trial participants at 12 months was assessed in the same way as for the European guidelines. For the US, targets were obtained from the American College of Cardiology (ACC) / American Heart Association (AHA) for BP (<130/80 mm Hg)1 and from the AHA / ACC Foundation for low density lipoprotein cholesterol (<70 mg/dL [1.8 mmol/L; or non-high density lipoprotein cholesterol of <100 mg/dL [2.6 mmol/L]] for those with a prior event, otherwise <100 mg/dL [2.6 mmol/L]; or non-high density lipoprotein cholesterol of <130 mg/dL [3.4 mmol/L]) and antiplatelet therapy for secondary prevention.2 The most recent US guideline for the treatment of cholesterol focuses on the appropriate intensity of statin therapy as opposed to target cholesterol levels.3 UK targets were obtained from National Institute for Health and Care Excellence (NICE) guidelines (BP <140/90 mm Hg,4 total cholesterol <5 mmol/L,5 and antiplatelet therapy for secondary prevention6-8).

*Results*

*Appendix 1 Table 1.* Achievement of treatment targets by guideline at 12 months

|  |  |  |  |
| --- | --- | --- | --- |
| Target  | Polypill n/N (crude %) | Usual care n/N (crude %) | RRa (95% CI) |
| **UK guidelines**  |
| BP  | 887/1393 (64%) | 794/1347 (59%) | 1.08 (1.02-1.14)\* |
| TC  | 1154/1371 (84%) | 1062/1333 (80%) | 1.06 (1.02-1.10)\* |
| Antiplatelet  | 1038/1086 (96%) | 1031/1078 (96%) | 1.00 (0.98-1.01) |
| BP and TC and antiplateletb  | 746/1393 (54%) | 642/1352 (47%) | 1.13 (1.05-1.22)\* |
| **US guidelines**  |
| BP  | 585/1393 (42%) | 447/1347 (33%) | 1.27 (1.16-1.40)\* |
| LDL | 524/1343 (39%) | 443/1294 (34%) | 1.13 (1.02-1.25)\* |
| Antiplatelet  | 1038/1086 (96%) | 1031/1078 (96%) | 1.00 (0.98-1.01) |
| BP and LDL and antiplateletb  | 223/1386 (16%) | 158/1343 (12%) | 1.37 (1.13-1.66)\* |
| Non-HDL cholesterol  | 608/1364 (45%) | 560/1323 (42%) | 1.05 (0.96-1.14) |

BP=blood pressure, CI=confidence interval, HDL=high density lipoprotein, LDL=low density lipoprotein cholesterol, RR=risk ratio, TC=total cholesterol

\*p<0.05 after Holm-Bonferroni correction for multiple testing of targets within the same guideline

aRRs were obtained from a log-binomial regression model as described in the methods section

bAntiplatelet target only applicable to people with established cardiovascular disease

*References*

1. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SCJ, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017

2. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-73

3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz N, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Sanford Schwartz J, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45.

4. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. CG127. https://www.nice.org.uk/guidance/cg127 (Accessed 15 September 2017). London: NICE; 2011.

5. National Institute for Health and Care Excellence. Secondary prevention of coronary heart disease. Indicator ID NM118. https://www.nice.org.uk/Media/Default/Standards-and-indicators/QOF%20Indicator%20Key%20documents/nm118-chd-guidance.pdf (Accessed 15 September 2017). London: NICE; 2015.

6. National Institute for Health and Care Excellence. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease. CG172. https://www.nice.org.uk/guidance/cg172 (Accessed 15 September 2017). London: NICE; 2013.

7. National Institute for Health and Care Excellence. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. CG68. https://www.nice.org.uk/guidance/cg68 (Accessed 15 September 2017). London: NICE; 2008.

8. National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. CG147. https://www.nice.org.uk/guidance/cg147 (Accessed 15 September 2017). London: NICE; 2012.